Intravascular Imaging-Guiding PCI in Complex Coronary Lesions Linked to Better Outcomes: The RENOVATE-COMPLEX-PCI Study
Key Points: Intravascular imaging-guided PCI shows promise in improving outcomes for patients with complex coronary artery lesions, with a 36% reduction on the primary... Read more.
TARGET Trial: On-site CT-FFR Feasible and Effective in stable CAD
Key points: The TARGET trial is the first randomized trial designed to assess the impact of an on-site CT-FFR strategy using machine learning compared to standard... Read more.
HALO – Baxdrostat Fails to Beat Placebo for Blood Pressure Reduction in Uncontrolled Hypertension
Key Points Baxdrostat, a highly selective aldosterone synthase inhibitor, reduced systolic blood pressure as compared with placebo among patients with resistant... Read more.
Evolocumab Effect on Plaque Characteristics in Stable CAD Patients
Key Points The YELLOW III study aimed to assess the effect of 26 weeks of evolocumab on plaque morphology using intravascular imaging (OCT and NIRS/IVUS) and peripheral... Read more.
No difference in Heart Failure Outcomes with Advanced Imaging modalities vs SPECT: The AIMI-HF Trial
Key Points: Imaging may be underused in patients with ischemic heart failure (HF) to evaluate ischemia/viability and guide management. The Alternative Imaging Modalities... Read more.
Viability Not Linked to Survival or LV improvement: The REVIVED-BCIS2 Randomized Trial
Key Points: -It is unclear whether myocardial viability tests should be used to guide decisions about revascularization in patients with ischemic cardiomyopathy... Read more.
Atorvastatin Reduced Left Ventricular Dysfunction From Anthracyclines: The STOP-CA Trial
Key Points -Anthracycline therapy is associated with the development of heart failure, yet anthracyclines are among the most widely used and most effective... Read more.
CLEAR Outcomes – Bempedoic Acid reduces Cardiovascular Events among Statin-Intolerant Patients
Key Points Bempedoic acid, an ATP citrate lyase inhibitor, has been shown to reduce LDL cholesterol concentrations by 17% to 28% in clinical trials. However, data... Read more.
BrigHTN: Baxdrostat, an aldosterone synthase inhibitor, showed dose-related reductions in blood pressure and safely and effectively lowers blood pressure in patients with resistant hypertension
Key Points In a Phase 2 randomized trial, baxdrostat, a highly potent and selective aldosterone synthase inhibitor, had dose-related reductions in blood pressurein... Read more.
FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension
Key Points Hypertension remains a major public health threat contributing significantly to rates of ischemic heart disease and strokes worldwide despite a wide array... Read more.